451 related articles for article (PubMed ID: 28540419)
1. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
2. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
3. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
5. PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers.
Vrachimis A; Ferentinos K; Demetriou E; Ioannides C; Zamboglou N
Hell J Nucl Med; 2020; 23(3):339-345. PubMed ID: 33306762
[TBL] [Abstract][Full Text] [Related]
6. The future of choline PET in the era of prostate specific membrane antigen.
Evangelista L; Cuppari L; Zattoni F; Mansi L; Bombardieri E
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):19-28. PubMed ID: 29383928
[TBL] [Abstract][Full Text] [Related]
7. PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
10. PSMA-negative prostate cancer and the continued value of choline-PET/CT.
Alberts I; Sachpekidis C; Fech V; Rominger A; Afshar-Oromieh A
Nuklearmedizin; 2020 Feb; 59(1):33-34. PubMed ID: 31766065
[No Abstract] [Full Text] [Related]
11. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
13. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria.
Fanti S; Hadaschik B; Herrmann K
J Nucl Med; 2020 May; 61(5):678-682. PubMed ID: 31806774
[TBL] [Abstract][Full Text] [Related]
14. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.
Bagguley D; Ong S; Buteau JP; Koschel S; Dhiantravan N; Hofman MS; Emmett L; Murphy DG; Lawrentschuk N
Future Oncol; 2021 Jun; 17(17):2225-2241. PubMed ID: 33724868
[TBL] [Abstract][Full Text] [Related]
15. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
16.
Fendler WP; Eiber M; Beheshti M; Bomanji J; Ceci F; Cho S; Giesel F; Haberkorn U; Hope TA; Kopka K; Krause BJ; Mottaghy FM; Schöder H; Sunderland J; Wan S; Wester HJ; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1014-1024. PubMed ID: 28283702
[TBL] [Abstract][Full Text] [Related]
17. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
18. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
19. [The role of PSMA PET-CT in patients with metastatic prostate cancer].
von Hardenberg J; Büsing KA; Nuhn P; Ritter M
Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
